Related references
Note: Only part of the references are listed.Pericytes secrete pro-regenerative molecules in response to platelet-derived growth factor-BB
Abderahim Gaceb et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2018)
Induction of Axon Growth in the Adult Brain: A New Approach to Restoration in Parkinson's Disease
Shalini Padmanabhan et al.
MOVEMENT DISORDERS (2018)
The pericyte secretome: Potential impact on regeneration
Abderahim Gaceb et al.
BIOCHIMIE (2018)
Neuroprotective effects of voluntary running on cognitive dysfunction in an α-synuclein rat model of Parkinson's disease
Erin K. Crowley et al.
NEUROBIOLOGY OF AGING (2018)
Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease
Gerard W. O'Keeffe et al.
PARKINSONISM & RELATED DISORDERS (2018)
miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons
Anna-Elisa Roser et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Emerging Issues in AAV-Mediated In Vivo Gene Therapy
Pasqualina Colella et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data
Napoleon Torres et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models
Xiaomin Su et al.
MOLECULAR THERAPY (2017)
Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: A systematic review and meta-analysis
Shane V. Hegarty et al.
PARKINSONISM & RELATED DISORDERS (2017)
Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion
David Reyes-Corona et al.
PLOS ONE (2017)
Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats
Filipe C. Matheus et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
How can rAAV--synuclein and the fibril -synuclein models advance our understanding of Parkinson's disease?
Laura A. Volpicelli-Daley et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Pericytes of the neurovascular unit: key functions and signaling pathways
Melanie D. Sweeney et al.
NATURE NEUROSCIENCE (2016)
Platelet-derived growth factor-BB has neurorestorative effects and modulates the pericyte response in a partial 6-hydroxydopamine lesion mouse model of Parkinson's disease
Thomas Padel et al.
NEUROBIOLOGY OF DISEASE (2016)
Retrograde Axonal Degeneration in Parkinson Disease
Patricia Tagliaferro et al.
JOURNAL OF PARKINSONS DISEASE (2016)
Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease
Enrique Garea-Rodriguez et al.
PLOS ONE (2016)
Viral vector delivery of neurotrophic factors for Parkinson's disease therapy
Martin J. Kelly et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2015)
Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy
Andrii Domanskyi et al.
HUMAN GENE THERAPY (2015)
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients
Gesine Paul et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Enhanced Efficacy of the CDNF/MANF Family by Combined Intranigral Overexpression in the 6-OHDA Rat Model of Parkinson's Disease
Oscar Cordero-Llana et al.
MOLECULAR THERAPY (2015)
Trophic Factors for Parkinson's Disease: To Live or Let Die
C. Warren Olanow et al.
MOVEMENT DISORDERS (2015)
Gene therapy for Parkinson's disease: a decade of progress supported by posthumous contributions from volunteer subjects
Raymond T. Bartus
Neural Regeneration Research (2015)
Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents
Shuke Nie et al.
NEUROPHARMACOLOGY (2015)
AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model
Xinmiao Ren et al.
EXPERIMENTAL NEUROLOGY (2013)
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits
Miguel M. Carvalho et al.
MOLECULAR NEURODEGENERATION (2013)
Trophic Factor Gene Therapy for Parkinson's Disease
Jeffrey H. Kordower et al.
MOVEMENT DISORDERS (2013)
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating clinical proof-of-concept for AAV-neurturin (CERE-120) in Parkinson's disease
Raymond T. Bartus et al.
NEUROBIOLOGY OF AGING (2013)
Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)
Christopher D. Herzog et al.
NEUROBIOLOGY OF DISEASE (2013)
BENEFITS OF PUTAMINAL GDNF INFUSION IN PARKINSON DISEASE ARE MAINTAINED AFTER GDNF CESSATION
Nikunj K. Patel et al.
NEUROLOGY (2013)
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Raymond T. Bartus et al.
NEUROLOGY (2013)
Rodent models of Parkinson's disease: beyond the motor symptomatology
Filipa L. Campos et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2013)
Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease
Susanne Back et al.
BRAIN AND BEHAVIOR (2013)
CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery After MPTP Treatment in Mice
Mikko Airavaara et al.
CELL TRANSPLANTATION (2012)
Do alpha-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?
Hanna S. Lindgren et al.
EXPERIMENTAL NEUROLOGY (2012)
α-Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Mickael Decressac et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease
Mickael Decressac et al.
BRAIN (2011)
The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinson's disease
Rui D. S. Prediger et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Neurotrophic factors for the treatment of Parkinson's disease
Aideen M. Sullivan et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2011)
Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease
Merja H. Voutilainen et al.
EXPERIMENTAL NEUROLOGY (2011)
Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease
R. Mark Richardson et al.
MOLECULAR THERAPY (2011)
Bioactivity of AAV2-Neurturin Gene Therapy (CERE-120): Differences Between Parkinson's Disease and Nonhuman Primate Brains
Raymond T. Bartus et al.
MOVEMENT DISORDERS (2011)
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease
Raymond T. Bartus et al.
NEUROBIOLOGY OF DISEASE (2011)
Image-guided convection-enhanced delivery of GDNF protein into monkey putamen
Francisco Gimenez et al.
NEUROIMAGE (2011)
Optimized cannula design and placement for convection-enhanced delivery in rat striatum
Dali Yin et al.
JOURNAL OF NEUROSCIENCE METHODS (2010)
Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics Laboratory investigation
Dali Yin et al.
JOURNAL OF NEUROSURGERY (2010)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling
Ethan A. Winkler et al.
MOLECULAR NEURODEGENERATION (2010)
Real-time MR Imaging With Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 Vectors
Xiaomin Su et al.
MOLECULAR THERAPY (2010)
Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging
Robert D. Bell et al.
NEURON (2010)
Single Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in C57BL/6 Mice Models Early Preclinical Phase of Parkinson's Disease
Rui D. S. Prediger et al.
NEUROTOXICITY RESEARCH (2010)
Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine
Ronise M. Santiago et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
Risk is in the Air An Intranasal MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine) Rat Model of Parkinson's Disease
Rui D. S. Prediger et al.
INTERNATIONAL SYMPOSIUM ON OLFACTION AND TASTE (2009)
Clinically Relevant Effects of Convection-Enhanced Delivery of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Aged Rhesus Monkeys
Louisa C. Johnston et al.
HUMAN GENE THERAPY (2009)
Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys
Xiaomin Su et al.
HUMAN GENE THERAPY (2009)
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks et al.
LANCET NEUROLOGY (2008)
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum
Christopher D. Herzog et al.
MOLECULAR THERAPY (2008)
Placebo influences on dyskinesia in Parkinson's disease
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
GDNF in Parkinson disease: An object lesson in the tyranny of type II
Michael Hutchinson et al.
JOURNAL OF NEUROSCIENCE METHODS (2007)
Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo
Pivi Lindholm et al.
NATURE (2007)
AAV2 - mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease
Mehdi Gasmi et al.
NEUROBIOLOGY OF DISEASE (2007)
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D. Herzog et al.
MOVEMENT DISORDERS (2007)
Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal
John T. Slevin et al.
JOURNAL OF NEUROSURGERY (2007)
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: Histological, neurochemical, motor and memory alterations
MM Ferro et al.
JOURNAL OF NEUROSCIENCE METHODS (2005)
Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified neurturin construct
L Fjord-Larsen et al.
EXPERIMENTAL NEUROLOGY (2005)
AAV2-mediated gene delivery to monkey putamen: Evaluation of an infusion device and delivery parameters
LM Sanftner et al.
EXPERIMENTAL NEUROLOGY (2005)
Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain
S Love et al.
NATURE MEDICINE (2005)
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor
JT Slevin et al.
JOURNAL OF NEUROSURGERY (2005)
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study
NK Patel et al.
ANNALS OF NEUROLOGY (2005)
Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease
C Lo Bianco et al.
NEUROBIOLOGY OF DISEASE (2004)
Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus)
A Eslamboli et al.
EXPERIMENTAL NEUROLOGY (2003)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a Rhesus monkey model of Parkinson's disease
HJ Li et al.
NEUROLOGICAL RESEARCH (2003)
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
JG Nutt et al.
NEUROLOGY (2003)
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys
R Grondin et al.
BRAIN (2002)
Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease
Y Oiwa et al.
BRAIN RESEARCH (2002)
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets
MM Iravani et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Towards a neuroprotective gene therapy for Parkinson's disease:: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model
A Björklund et al.
BRAIN RESEARCH (2000)
Long-term rAAV-mediated gene transfer of GDNF in the rat parkinson's model:: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system
D Kirik et al.
JOURNAL OF NEUROSCIENCE (2000)
The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages
M Aoi et al.
NEUROSCIENCE RESEARCH (2000)
Share Paper
